What is claimed is:
1. A compound containing the theophylline moiety of formula I,
53
wherein
R1 is (CH2)2CH3;R2 is a member selected from the group
54
wherein R4 is a member selected from the group of H, (CH2)n CH3, X,NH2 and NO2 and X designates F, Cl, Br or I
wherein R5 is a member selected from the group of H,
55
wherein
R3 is a member selected from the group of halogen, hydroxyl group, a saturated straight chain of 1-3 carbon atoms and when one of R3 is hydrogen, n is 0, 1, 2 or 3.
2. A compound containing the theophylline moiety of formula II
56
wherein
R1 is (CH2)n; CH3; R2 is a member selected from the group of
57
wherein
R4 is a member selected from the group of H, (CH2)n CH3, X, NH2 and NO2; X designates F, Cl, Br or I.
R3 is a member selected from the group of H,
58
R3 is a member selected from the group of halogen, hydroxyl group (OH), a saturated straight chain of 1-3 carbon atoms and when one of R3 is hydrogen; n is 0, 1, 2 or 3.
3. A pharmaceutical composition which has corpus carvernosal relaxation activity containing a compound of formula I as defined in claim 1.
4. A pharmaceutical composition which has corpus carvernosal relaxation activity containing a compound of formula II as defined in claim 2.
5. A process for the preparation of a compound of formula I according to claim 1 which comprises the reacting of a compound of formula
59
in which R1CH2CH(CH3)2 or R1CH3
with 1,2-dibromoethane as shown in step a
60
to produce a monobromo compound which is then reacted in step b with the piperazinyl ring which is a secondary amine, then adding NaOH to precipitate NaBr and obtaining the product which contains the piperazinyl ring.
6. A process for the preparation of a compound of formula II according to claim 2 which comprises the reaction of a compound of formula
61
R1CH2CH(CH3)2 or R1CH3
with 1,2-dibromoethane
to produce a monobromo compound according to reaction a
62
and said monobromo compound is reacted with a N-substituted piperazine according to reaction b or with piperazine according to reaction c to produce a compound wherein the N is not substituted
63
and said compound is reacted according to d to produce a compound II
64
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A cosmetic composition for the treatment of keratinic fibers, in particular human hair, comprising:
a. at least one cationic amino-functional silicone;
b. at least one vitamin from the B series; and
c. a cosmetic support.
2. The cosmetic composition according to claim 1, wherein the cationic amino-functional silicone is Silicone Quaternium-22.
3. The cosmetic composition according to claim 1, wherein the vitamin from the B series is selected from the group consisting of panthenol, pantolactone, pantothenic acid, pyridoxine and derivatives thereof, and nicotinamide.
4. The cosmetic composition according to claim 1, wherein cationic amino-functional silicone is included in an amount of 0.01 to 20.0 wt. %.
5. The cosmetic composition according to claim 1, further comprising at least one additional ingredient selected from the group consisting of a cationic surfactant, a cationic polymer, and an amphoteric polymer.
6. The cosmetic composition according to claim 1, further comprising at least one further silicone selected from the group consisting of dimethicones, amodimethicones and dimethiconols.
7. The cosmetic composition according to claim 6, wherein the further silicone has a viscosity of 40,000 to 80,000 mPa\xb7s.
8. The cosmetic composition according to claim 1, further comprising at least one active substance selected from the group consisting of carnitine, taurine, coenzyme Q-10, ectoine, and a purine or a derivative or physiologically acceptable salt thereof.
9. A method for the treatment of keratinic fibers, comprising:
applying a cosmetic composition according to claim 1 on to the keratinic fibers; and
rinsing the hair after an exposure period ranging between a few seconds and 45 minutes.